CITIC Securities

Chinese game developer XD is set to launch the roadshow for its Hong Kong IPO, having filed post-listing hearing documents with the Hong Kong Stock Exchange (HKEX).

Alphamab Oncology, a Chinese biopharmaceutical firm, has launched a roadshow for an up to HK$1.83bn ($233.8m) listing, according to a source close to the deal.

Pharmaceutical research and development platform Pharmaron Beijing Co has bagged HK$4.6bn ($588m) after sealing its Hong Kong public offering at the top of the price guidance.

China Construction Bank, the largest originator in the Chinese RMBS market, is planning to launch a Rmb11.52bn internationally rated four tranche deal next Wednesday. It will include ratings from S&P Global Ratings and, for the first time, its local subsidiary.

Yeahka, a payments technology platform, is planning to float on Hong Kong’s stock exchange. The Chinese firm hopes to raise around $300m from the deal, said a source familiar with the matter.

Alphamab Oncology, a Chinese biopharmaceutical company, kicked off pre-deal investor education for a potential $250m IPO on Monday after gaining approval to list from the Hong Kong Stock Exchange.

OneConnect Financial Technology, an arm of Chinese financial conglomerate Ping An Group, has set the ball rolling for an up to $100m US IPO, having previously sought to list in Hong Kong.

Alibaba Group Holding has kicked off its up to $13.4bn Hong Kong IPO, set to be the largest listing on the bourse for nearly a decade. Bankers are confident the deal will be a success, but they are navigating challenging times in the city’s stock market, which plunged this week as violence during protests escalated. Jonathan Breen reports.

Volkswagen Finance (China) has returned to the Chinese auto loan ABS market after a two-year break. The company priced the senior tranche of its Rmb5.97bn ($851) deal at the lower end of guidance.

Beijing Hyundai Auto Finance and SAIC-GMAC Automotive Finance priced their Chinese auto loan ABS transactions on Tuesday.

Pharmaron Beijing Co, a pharmaceutical research and development service platform, has launched its Hong Kong SAR flotation, aiming to raise up to HK$4.6bn ($587.8m), said a source familiar with the matter.

BMW Auto Finance (China) has wrapped up its last foray of the year into the Chinese auto loan ABS market with a tightly priced deal. A diverse group of investors took up the senior tranche of the Rmb8bn ($1.14bn) trade, said bankers.